ViaDerma, is a specialty pharmaceutical company committed to bringing new products to market through innovative research & development. ViaDerma licenses products in fields of medicine ranging from infectious diseases to wound care. Based in Los Angeles, CA, ViaDerma recently published company updates for 2020 and a summary of what is to come in 2021, which is nothing short of massive.
According to their recent press release, ViaDerma’s President & CEO, Dr. Christopher Otiko offered commentary on company progress. “Despite the challenges faced by many companies, including ViaDerma during 2020, our Company has been able to make very significant strides forward that have laid the foundation for what we believe could be a record-breaking year.”
Some of ViaDerma’s significant highlights of 2020 include:
1: The FDA Approved Registration Vitastem
The FDA approved registration of a new 55 ml Vitastem spray bottle. Vitastem is now one of the world’s strongest topical antibiotics. Vitastem kills all harmful Gram-positive and Gram-negative bacteria that have been available for testing (bacteria that is associated with eczema, psoriasis, acne, diabetic wounds, cuts and others).
This came at the request of hospitals that have tested the product. A larger spray version will be easier to apply the medication to large wounds.
2: Increased Demand by Major Hospitals, Health Insurers, and Universities
According to ViaDerma, a large national hospital chain and a major health insurance company have completed successful testing of the Vitastem product. ViaDerma is now in the final stages of discussions to determine the size of the initial purchase.
In addition, ViaDerma completed successful product testing with a major midwestern university with whom is also in discussions regarding their initial product purchase.
3: Officially Launched Liberdol – A New Pain Relief Product
The analgesics market in the U.S. is estimated to be more than $12 billion dollars. ViaDerma seems to be positioned well to accrue market share here too.
4: Global Growth Expansion
ViaDerma has initiated discussions with a major global medical nonprofit that has expressed interest in purchasing Vitastem for use by their doctors and medical staff in treating patients.
5: Growth Funding Secured
An extended line of credit was secured for financing future manufacturing.
6: Preliminary Sales Forecast in 2021
ViaDerma anticipates sales to top 500,000 units in 2021. Vitastem currently retails for $99 but currently on sale for $79 on their website and on Amazon.com. This could lead to nearly $40,000,000 in revenue this year alone with initial US demand.
7: Targeting Multi-Billion Yearly Revanue Markets
ViaDerma is developing products in many fields of use, including these lucrative markets:
- Topical antibiotics – $6 billion/year
- Toenail antifungal drugs – $3 billion/year
- Diabetic amputations – $4.6 billion/year
- Global acne – $11.86 billion/year
- Psoriasis – $7.3 billion/year
- Eczema – $2.5 billion/year
Other potential markets ViaDerma is targeting include burns, anti-aging/wrinkle remover cream, medical cannabis, male-pattern baldness, skin cancer, erectile dysfunction, and pain management with Liberdol.
More About their lead FDA Approved Product Vitastem
All known antibiotics (other than Vitastem) primarily use what’s called a chemical “mechanism of kill” only, whereby the antibiotic attempts to kill the bacteria slowly by applying (if topical) or absorbing (if oral) more and more of the medicine over a period of time as it is taken as prescribed. While this can be somewhat effective, it takes much longer. Unfortunately, this also allows for bacteria to do what bacteria does: evolve and develop resistance to the medicine.
That’s where Vitastem is different…
Vitastem uses both a chemical and a physical mechanism to kill and fight pathogens. The physical mechanism of kill is a key feature of Vitastem’s strength and key to reducing the appearance of scars.
Vitastem’s patent-pending, specialized combination of ingredients has hacked the delivery formula that enables medicine to be transported at 10x the strength and depth of other products in the marketplace today. This formula stimulates the cell wall such that it is up to 10x more permeable than normal, allowing for substantially more medicine to enter into the cell, overwhelming and killing the bacteria so quickly that it does not have time to adapt and develop resistance. This highly concentrated and rapid delivery of medicine to the site of need is what has many patients seeing results in 24 hours versus 5 to 7 days (as is the case with other products that treat the same conditions).
In addition to treating the condition, Vitastem also infuses skin cells damaged by the infection with vitamin D3 and vitamin C. Skin is left treated and rejuvenated!
Because Vitastem is a topical antibiotic, it is safer for your liver than oral OTC or prescription treatments.
Overview of ViaDerma
ViaDerma, Inc. (OTC: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. For more information, visit: Viadermalicensing
Any forecast of future performance is a “forward looking statement” under securities laws. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.
